Parkinson's disease has become one of the best-studied neurodegenerative disorders in medicine.

Over the past several decades, researchers have identified numerous biological abnormalities associated with the disease. These include α-synuclein aggregation, mitochondrial dysfunction, lysosomal impairment, altered proteostasis, oxidative stress, neuroinflammatory responses, abnormalities of glucocerebrosidase biology, and multiple genetic pathways linked to inherited forms of parkinsonism.

Many of these discoveries transformed how researchers thought about Parkinson's disease.

Some were supported by human genetics.

Others emerged from neuropathology, experimental biology, longitudinal cohort studies, or increasingly sophisticated animal models.

Several progressed into large international clinical trials.

Yet despite remarkable advances in understanding disease biology, no therapy has yet been conclusively shown to produce broadly accepted disease modification in Parkinson's disease.

This contrast raises an important question.

If researchers understand far more about Parkinson's disease today than they did thirty years ago, why has slowing its progression proved so difficult?

The answer is more complicated than simply saying that clinical trials failed.

Nor does it mean that the underlying biological hypotheses were necessarily incorrect.

Rather, Parkinson's disease has repeatedly demonstrated how difficult it is to translate biological insight into meaningful and durable clinical benefit.

Understanding why requires appreciating the extraordinary complexity of the disease itself.

A proposed therapeutic target must genuinely contribute to ongoing disease progression rather than simply accompany it.

The therapeutic agent must reach the relevant anatomical compartment within the human brain and engage the intended molecular target sufficiently to modify its biology.

Treatment must begin while the relevant pathological process remains therapeutically modifiable.

Clinical trials must distinguish true slowing of disease progression from symptomatic improvement.

And investigators must measure progression accurately in a disorder that evolves slowly, varies substantially between individuals, and affects multiple neurological systems beyond movement alone.

Failure at any one of these stages may prevent an otherwise promising therapy from demonstrating clinical benefit.

Equally important, Parkinson's disease may not progress through one universal biological sequence.

Patients who satisfy the same clinical diagnostic criteria can differ markedly in genetic background, dominant molecular abnormalities, pathological burden, rate of progression, and clinical phenotype.

A treatment directed at one biological pathway may therefore prove highly relevant for some patients while having little effect in others.

The biological idea was both logical and deceptively straightforward.

If a biological process contributes to progressive neuronal dysfunction or neurodegeneration, then modifying that process might slow the progression of Parkinson's disease.

This principle extended across nearly every proposed disease-modifying therapy.

Whether researchers targeted α-synuclein aggregation, mitochondrial dysfunction, oxidative stress, lysosomal impairment, neuroinflammation, calcium homeostasis, glucocerebrosidase biology, or neurotrophic signalling, the underlying therapeutic logic remained remarkably similar.

Identify a biologically important pathway.

Modify that pathway.

Preserve vulnerable neural systems.

Slow disease progression.

At first glance, the reasoning appears compelling.

Yet every step depends on assumptions that are considerably more difficult to prove than they initially appear.

The first assumption is that the selected biological process is sufficiently important to drive continued disease progression.

Not every abnormality observed in Parkinson's disease necessarily occupies that role.

Some pathological changes may initiate disease.

Others may accelerate progression.

Some may arise secondarily as neurons become dysfunctional.

Still others may represent adaptive or protective cellular responses attempting to limit injury.

Distinguishing among these possibilities is one of the greatest challenges in neurodegenerative research.

Finding an abnormality is therefore not the same as identifying the critical therapeutic target.

The second assumption is that successfully engaging the target will meaningfully alter disease biology.

Target engagement itself is not a single concept.

A drug may achieve measurable concentrations in blood while failing to penetrate the brain adequately.

It may enter the central nervous system but fail to reach the neuronal compartment in which the relevant pathology resides.

An antibody may bind extracellular α-synuclein while having little influence on intracellular protein species that may contribute more substantially to disease.

Similarly, demonstrating receptor occupancy or biochemical target engagement does not automatically establish that the broader neurodegenerative process has been altered.

Each level of target engagement provides different information.

None alone guarantees therapeutic success.

The third assumption concerns timing.

By the time classical motor Parkinson's disease is diagnosed, substantial dysfunction and degeneration within the nigrostriatal dopaminergic system have often already occurred.

The precise extent varies between individuals and depends on how it is measured.

If therapies are introduced only after key neural systems have lost much of their functional reserve, modifying earlier biological events may produce only limited clinical benefit.

This possibility has become one of the strongest arguments for identifying Parkinson-related biology before conventional motor diagnosis.

At the same time, it remains a hypothesis rather than a universally proven explanation for previous therapeutic failures.

Earlier intervention alone cannot guarantee success if the selected biological target is not the principal driver of progression.

The fourth assumption is that slowing biology and slowing clinical progression are necessarily equivalent.

They are not.

A therapy may improve motor symptoms without altering the underlying disease process.

Conversely, a treatment might successfully modify one component of disease biology yet produce only subtle changes on conventional clinical rating scales over the duration of a trial.

Parkinson's disease progresses slowly, affects multiple neurological domains, and exhibits substantial variability between individuals.

Motor function, cognition, autonomic function, sleep, speech, gait, mood, and quality of life may progress at different rates and may not respond similarly to the same intervention.

Determining whether a therapy has genuinely modified disease therefore requires much more than observing symptomatic improvement in a single domain.

Finally, researchers increasingly recognised that Parkinson's disease is defined clinically but is unlikely to be biologically uniform.

Patients meeting identical clinical diagnostic criteria may differ substantially in genetics, molecular pathology, biomarker profiles, disease trajectories, and therapeutic responsiveness.

Rather than representing one completely homogeneous disorder, Parkinson's disease appears to encompass considerable biological heterogeneity.

Exactly how that heterogeneity should be classified—and whether it ultimately defines biologically distinct subgroups or represents variation along overlapping disease processes—remains an active area of investigation.

This distinction has important therapeutic implications.

If different biological mechanisms dominate in different patients, a treatment directed against one pathway may show only modest benefit when evaluated across a clinically heterogeneous trial population.

Whether biomarker-guided patient selection can overcome this challenge remains uncertain, but it has become one of the major directions of contemporary Parkinson's disease research.

The biological idea therefore evolved beyond the search for a single disease-modifying drug.

Increasingly, the challenge became understanding which biology should be targeted, in which patients, at what stage of disease, and how successful modification should be measured.

Those questions—not simply the discovery of new therapeutic targets—now lie at the centre of Parkinson's disease research.

The belief that Parkinson's disease could be slowed did not arise from a single discovery.

Instead, it emerged gradually as several independent lines of evidence appeared to converge on the same conclusion.

Human genetics identified biological pathways associated with Parkinson's disease.

Neuropathology revealed characteristic molecular abnormalities within affected brains.

Experimental models demonstrated that manipulating some of these pathways could preserve dopaminergic neurons or improve motor behaviour.

Longitudinal observational studies suggested that certain biological states or clinical features might influence disease risk or progression.

Together, these observations created growing optimism that the mechanisms driving Parkinson's disease were becoming increasingly understood—and that modifying them might alter the course of the disease itself.

Importantly, however, these different forms of evidence did not all answer the same scientific question.

Some identified biological associations.

Some suggested causality.

Some demonstrated mechanistic plausibility.

Others merely generated therapeutic hypotheses.

Understanding those distinctions is essential for interpreting why subsequent clinical trials proved so challenging.

Among the strongest evidence came from genetics.

Unlike observational associations, pathogenic genetic variants can provide direct evidence that disruption of specific biological pathways is sufficient to cause Parkinsonism in at least some individuals.

Rare autosomal-dominant forms of Parkinson's disease were linked to pathogenic variants or multiplications of the SNCA gene, demonstrating that abnormalities of α-synuclein biology can directly cause familial Parkinsonism.

Mutations in LRRK2, VPS35, PRKN, PINK1, DJ-1, and several other genes subsequently identified pathways involving mitochondrial quality control, lysosomal degradation, vesicular trafficking, protein homeostasis, and cellular stress responses.

One of the most influential discoveries involved GBA1.

Variants in GBA1, which encodes the lysosomal enzyme glucocerebrosidase, substantially increase the risk of Parkinson's disease and strengthened interest in lysosomal dysfunction as a potential contributor to α-synuclein accumulation and impaired protein clearance.

These discoveries transformed Parkinson's disease research.

Rather than suggesting a single universal mechanism, genetics increasingly indicated that multiple interconnected biological pathways may converge to produce overlapping clinical syndromes.

Equally important, genetics also introduced complexity.

Different genetic forms of Parkinsonism differ in penetrance, pathology, clinical phenotype, progression, and, in some cases, underlying neuropathology.

For example, biallelic PRKN-associated Parkinsonism often lacks the widespread Lewy pathology typically seen in sporadic Parkinson's disease.

These observations suggested that clinically similar patients might not share identical biological mechanisms.

That possibility remains central to modern therapeutic development.

Neuropathological studies provided another major source of optimism.

Lewy bodies and Lewy neurites had long been recognised as pathological hallmarks of Parkinson's disease.

The discovery that α-synuclein is a principal constituent of these inclusions suggested that abnormal protein folding and aggregation might play an important role in disease biology.

The genetic discoveries involving SNCA further strengthened this hypothesis.

Nevertheless, pathology alone cannot establish causality.

Finding a protein within pathological inclusions does not determine whether that protein initiated disease, accelerated progression, accumulated secondarily, or represented part of a protective cellular response.

Even today, important questions remain unresolved.

Which molecular species of α-synuclein are most toxic?

Do soluble oligomers, fibrillar aggregates, or mature inclusions contribute differently to disease progression?

Does inclusion formation itself promote neuronal injury, or can sequestration of misfolded proteins sometimes reduce toxicity?

These questions remain active areas of investigation.

Neuropathology therefore provided compelling biological clues.

It did not, by itself, identify the optimal therapeutic target.

Experimental models added another important layer of evidence.

Toxin models, including those based on MPTP and 6-hydroxydopamine, demonstrated that selective injury to dopaminergic neurons could produce Parkinsonian motor syndromes.

Other models based on α-synuclein overexpression, seeded aggregation, or genetic manipulation reproduced selected molecular features of the disease.

Across many of these systems, interventions targeting mitochondrial dysfunction, oxidative stress, lysosomal pathways, inflammation, α-synuclein biology, or neurotrophic signalling often produced encouraging results.

Some preserved dopaminergic neurons.

Others reduced pathological protein accumulation.

Many improved motor behaviour.

These findings demonstrated that modifying biological pathways could influence disease-related processes under controlled experimental conditions.

At the same time, important limitations became increasingly apparent.

No currently available animal model fully reproduces the slowly progressive, age-associated, multisystem neurodegeneration observed in idiopathic Parkinson's disease.

Many toxin models produce rapid neuronal injury rather than decades of progressive degeneration.

Genetic models often reproduce molecular abnormalities without extensive neuronal loss.

In many experiments, treatment begins before or very soon after disease induction—quite different from the clinical situation, in which therapy is initiated after symptoms emerge.

Preclinical studies may also be influenced by publication bias, variable methodological quality, and outcome measures that do not translate directly to human disease.

Consequently, success in experimental models demonstrates biological plausibility.

It does not establish clinical efficacy.

Population studies also contributed substantially to enthusiasm for disease modification.

Researchers identified associations between Parkinson's disease and numerous biological or environmental factors, including serum urate concentrations, physical activity, smoking, caffeine consumption, diabetes, and several medication classes.

Some associations appeared biologically plausible.

Others were supported by complementary laboratory evidence.

These observations encouraged drug repurposing because approved medications already possessed established manufacturing processes and safety data for their original indications.

However, observational studies are designed to identify associations—not causation.

Confounding, reverse causation, selection bias, and measurement bias can all generate associations that disappear during randomized trials.

An exposure associated with lower disease risk is not necessarily a therapeutic target.

Likewise, modifying an associated biological variable does not guarantee that disease progression will change.

Several major Parkinson's disease trials would later illustrate this distinction.

Perhaps the most important change was conceptual.

For many years, Parkinson's disease research focused primarily on replacing dopamine and improving motor symptoms.

As biological understanding expanded, researchers increasingly asked whether the underlying disease process itself could be altered.

The therapeutic goal shifted from symptomatic treatment toward disease modification.

Importantly, this transition did not replace symptomatic research.

Both approaches continued to develop in parallel.

The crucial difference lay in the questions being asked.

Instead of asking,

"Can we improve movement?"

researchers increasingly asked,

"Can we change the biology responsible for progressive neurodegeneration?"

That question fundamentally reshaped Parkinson's disease research over the following three decades.

Taken together, genetics, neuropathology, experimental biology, and observational studies created a persuasive scientific rationale for pursuing disease-modifying therapies.

Each contributed an important piece of the puzzle.

Human genetics identified biologically important pathways.

Neuropathology revealed recurring molecular abnormalities.

Experimental models demonstrated mechanistic plausibility.

Observational studies generated therapeutic hypotheses.

What none of these approaches could establish, however, was whether modifying those pathways would meaningfully slow Parkinson's disease in patients.

That question could only be answered through carefully designed clinical trials.

And it was those trials that revealed just how difficult disease modification would prove to be.

Ultimately, every proposed disease-modifying strategy faced the same question.

Could modifying a biologically plausible pathway meaningfully slow the progression of Parkinson's disease in patients?

Over the past three decades, dozens of clinical programmes have attempted to answer that question.

Collectively, the results have been informative, although not every negative trial resolved why the intervention failed.

Not because they identified a therapy that clearly slowed Parkinson's disease, but because they revealed where translation repeatedly breaks down.

Importantly, these programmes should not be viewed simply as a series of negative trials.

Instead, each exposed a different obstacle separating biological plausibility from successful disease modification.

Rather than asking, "Which drugs failed?", a more useful question is:

"What did those failures teach us about why Parkinson's disease is so difficult to slow?"

One recurring lesson is that biological relevance does not necessarily imply therapeutic dominance.

A pathway may genuinely contribute to Parkinson's disease without being the principal determinant of ongoing progression.

Mitochondrial dysfunction illustrates this challenge.

Experimental studies consistently demonstrated mitochondrial abnormalities in dopaminergic neurons, while MPTP toxicity established that disruption of mitochondrial complex I could produce Parkinsonism.

These findings led to large clinical programmes evaluating therapies such as coenzyme Q10 and creatine.

The phase III QE3 trial of high-dose coenzyme Q10 was stopped for futility after interim analyses indicated that meaningful clinical benefit was unlikely.

Similarly, the NET-PD LS-1 trial found no convincing evidence that creatine slowed disease progression.

These studies did not demonstrate that mitochondrial biology is irrelevant to Parkinson's disease.

Rather, they showed that these particular interventions—at the doses, treatment durations, and disease stages studied—did not produce clinically meaningful slowing of progression.

Whether this reflects inadequate target engagement, intervention after irreversible injury, insufficient biological effect, or the fact that mitochondrial dysfunction is only one component of a much broader disease process remains uncertain.

A second lesson involved target engagement.

Delivering a therapeutic agent into the human brain—and demonstrating that it has meaningfully altered the relevant pathological process—is often considerably more difficult than laboratory studies suggest.

Neurotrophic-factor therapies illustrate this problem.

Experimental studies consistently demonstrated that glial cell line-derived neurotrophic factor (GDNF) and neurturin could support dopaminergic neuronal survival and function.

However, these large biological molecules required direct intracerebral delivery.

Clinical trials faced substantial challenges involving surgical targeting, tissue distribution, diffusion through diseased brain tissue, and sustained exposure.

The CERE-120 programme, which used viral-vector delivery of neurturin, demonstrated biological plausibility but failed to meet its primary clinical endpoints.

These studies did not necessarily prove that neurotrophic support cannot modify Parkinson's disease.

Instead, they illustrated a broader principle:

Even a biologically promising therapy cannot demonstrate clinical benefit if it fails to reach, engage, or sufficiently modify its intended target within the human brain.

Perhaps no therapeutic strategy illustrates this challenge better than α-synuclein immunotherapy.

The biological rationale was compelling.

Neuropathology identified α-synuclein within Lewy pathology.

Human genetics demonstrated that abnormalities of SNCA could directly cause familial Parkinsonism.

Experimental studies suggested that pathological α-synuclein species might spread between vulnerable neurons.

The hypothesis was therefore straightforward.

If disease progression depends partly on pathological α-synuclein, reducing that pathology might slow neurodegeneration.

Several monoclonal antibodies entered clinical development.

Cinpanemab, evaluated in the phase II SPARK trial, failed to demonstrate convincing clinical benefit, and development was discontinued.

Prasinezumab produced a more nuanced outcome.

The phase II PASADENA trial did not meet its primary endpoint, and imaging biomarkers did not demonstrate convincing disease modification.

The subsequent phase IIb PADOVA trial likewise failed to achieve statistical significance for its primary endpoint.

Nevertheless, exploratory analyses, numerical trends, and predefined subgroup findings were considered sufficiently encouraging for the programme to advance into phase III evaluation.

Prasinezumab remains clinically unproven. Its phase II primary efficacy endpoints were not met, although exploratory findings were considered sufficient to justify phase III testing.

Prasinezumab cannot presently be considered an effective disease-modifying therapy.

Equally, its continued development reflects the possibility that questions regarding patient selection, disease stage, endpoint sensitivity, or biological heterogeneity remain incompletely resolved.

The programme illustrates an important principle.

Failure to demonstrate efficacy does not necessarily invalidate α-synuclein biology.

Nor does it confirm that α-synuclein is the optimal therapeutic target.

It demonstrates only that the specific intervention tested has not yet convincingly slowed Parkinson's disease under the conditions studied.

Another important uncertainty also remains.

Most therapeutic antibodies primarily target extracellular α-synuclein.

Whether extracellular species represent the principal drivers of ongoing neurodegeneration—or whether intracellular aggregates, soluble oligomers, or other molecular conformations are more biologically important—remains incompletely understood.

Target engagement therefore depends not only on reaching the brain but also on modifying the biologically relevant molecular species.

Several disease-modification programmes originated from strong observational evidence.

Higher serum urate concentrations appeared associated with slower clinical progression in some observational studies.

This led to the SURE-PD3 trial evaluating inosine.

Although treatment successfully increased serum urate concentrations, it did not slow Parkinson's disease progression.

Similarly, epidemiological observations suggesting possible protective effects of calcium-channel blockers prompted the STEADY-PD III trial of isradipine.

Again, convincing evidence of disease modification was not demonstrated.

These programmes highlighted an important epidemiological principle.

An associated biological factor may function as a marker of disease biology rather than a modifiable causal mechanism.

Successfully altering the marker does not necessarily alter the disease itself.

More recently, glucagon-like peptide-1 (GLP-1) receptor agonists have generated considerable interest because of experimental evidence suggesting effects on inflammation, mitochondrial biology, insulin signalling, and neuronal survival.

Early studies of exenatide reported encouraging differences in motor outcomes following treatment.

However, the larger Exenatide-PD3 trial did not demonstrate evidence supporting exenatide as a disease-modifying therapy.

Readers should also be aware that The Lancet subsequently issued an Expression of Concern regarding the published trial report in 2026.

The editorial notice does not itself establish that the study's conclusions are incorrect, but it means the published findings should currently be interpreted with appropriate caution until the issues raised by the journal are fully resolved.

Other GLP-1 receptor agonists continue to be investigated.

A phase II trial of lixisenatide reported slower worsening of motor disability over twelve months compared with placebo.

These findings are scientifically encouraging.

However, the study was relatively short, gastrointestinal adverse effects were common, and the results require replication in larger trials before conclusions regarding disease modification can be drawn.

Taken together, these studies suggest that GLP-1 biology remains an active area of investigation.

They do not yet establish that the therapeutic class slows Parkinson's disease.

Viewed collectively, these trials reveal a recurring pattern.

Promising laboratory biology repeatedly entered clinical testing.

Some interventions demonstrated evidence of biological activity.

Some successfully modified their intended molecular targets.

Others achieved encouraging exploratory signals.

Yet convincing demonstration of durable disease modification remained elusive.

Importantly, the reasons differed from one programme to another.

In some cases, the therapeutic target itself may not have represented the principal driver of progression.

In others, target engagement may have been incomplete.

Some interventions may have been introduced after substantial neural injury had already occurred.

Others may have been tested in biologically heterogeneous populations, where any benefit within a subgroup became difficult to detect.

Current clinical outcome measures may also be insufficiently sensitive to detect modest slowing over the duration of many trials.

None of these explanations has been established as the universal reason for previous failures.

Each remains a plausible contributor supported to varying degrees by different lines of evidence.

That distinction is important.

The history of Parkinson's disease research should not be interpreted as evidence that disease modification is impossible.

Rather, it demonstrates that slowing a slowly progressive, biologically heterogeneous neurodegenerative disorder is substantially more difficult than identifying a promising biological target.

The greatest challenge may therefore not be discovering another therapeutic pathway.

It may be learning how to target the right biology, in the right patients, at the right stage of disease, while measuring outcomes that genuinely reflect changes in disease progression.

Slowing Parkinson's disease requires far more than finding a promising target.

Researchers must identify the right biology, treat at the right time, reach the right cells, and measure true disease progression.

Failure at any one step can prevent an effective therapy from showing clinical benefit.

After more than three decades of intensive research, one conclusion has become increasingly clear.

The greatest obstacle to slowing Parkinson's disease is probably not the lack of plausible biological targets.

It is the extraordinary complexity of translating biological understanding into clinically meaningful disease modification.

That complexity exists at every level of the disease.

We still do not know which biological processes initiate Parkinson's disease in most individuals.

We do not know whether the dominant drivers of progression remain the same throughout the disease course.

We cannot yet identify, with sufficient precision, which biological pathway is most important in an individual patient.

And we still lack universally accepted biomarkers capable of demonstrating that a therapy has truly altered the natural history of the disease.

The challenge is therefore no longer simply discovering another promising molecule.

It is understanding precisely what should be targeted, when it should be targeted, in whom it should be be targeted, and how success should be measured.

One of the most important developments in recent years has been the growing recognition that Parkinson’s disease is clinically defined but shows substantial and increasingly measurable biological heterogeneity.

Patients who satisfy the same diagnostic criteria may differ substantially in genetics, molecular pathology, biomarker profiles, progression rate, treatment responsiveness, and the neural systems predominantly affected.

Some individuals appear to have strong evidence of α-synuclein-associated biology.

Others may have prominent lysosomal dysfunction, mitochondrial impairment, altered proteostasis, neuroinflammatory responses, or combinations of several interacting processes.

These pathways should not be viewed as mutually exclusive.

They interact continuously throughout the disease.

Their relative importance may also change as the disease progresses.

Exactly how these biological differences should be classified—and whether they ultimately represent distinct disease subtypes or overlapping pathological continua—remains uncertain.

This heterogeneity has important therapeutic implications.

A treatment directed against one pathway may produce genuine benefit within a biologically defined subgroup while showing little overall effect in a clinically heterogeneous trial population.

This possibility has become one of the principal motivations for biomarker-guided patient stratification.

Whether precision medicine will ultimately improve disease-modifying therapy remains an important but still unanswered question.

Another important possibility concerns timing.

Neurodegeneration is unlikely to represent a single irreversible event.

Instead, Parkinson's disease probably evolves through multiple interacting biological processes.

An initiating abnormality may trigger downstream changes involving protein aggregation, mitochondrial dysfunction, impaired lysosomal function, inflammation, synaptic dysfunction, axonal injury, network reorganisation, and loss of compensatory mechanisms.

Some downstream processes may eventually become partially self-sustaining.

If so, successfully modifying the initiating biology after widespread secondary changes have developed might produce only limited clinical benefit.

This hypothesis remains incompletely proven.

However, it offers one biologically plausible explanation for why therapies directed against apparently important pathways may have limited effects once classical motor Parkinson's disease has become established.

It also illustrates why earlier intervention, although attractive in principle, cannot automatically be assumed to guarantee therapeutic success.

Earlier treatment is likely to be beneficial only if the correct biological process is targeted at the appropriate stage of disease.

One recurring lesson from previous clinical trials is that measuring disease modification is itself remarkably difficult.

Current clinical outcome measures, including the MDS-UPDRS, remain essential because they capture changes that matter directly to patients.

However, they do not measure ongoing neurodegeneration itself.

Motor scores may improve because of symptomatic benefit while disease biology continues to evolve.

Conversely, a therapy that modestly slows one aspect of disease biology may produce only subtle changes in clinical ratings over the duration of a typical trial.

Parkinson's disease also progresses across multiple domains.

Motor impairment, cognition, autonomic dysfunction, sleep, speech, gait, mood, disability, and quality of life may change at different rates.

A therapy might meaningfully influence one domain while producing relatively little measurable effect in another.

Determining what should constitute "disease slowing" therefore remains more complicated than demonstrating improvement on a single clinical scale.

For these reasons, considerable effort is now directed toward developing biomarkers capable of improving patient selection, demonstrating target engagement, monitoring biological response, and perhaps eventually serving as validated surrogate endpoints.

Several candidates—including α-synuclein seed-amplification assays, advanced imaging, digital biomarkers, and multimodal biomarker strategies—have shown encouraging progress.

At present, however, none has achieved universal acceptance as a validated surrogate endpoint for disease modification in Parkinson's disease.

The experience of the past thirty years suggests that expecting one universal disease-modifying therapy for every patient may be unrealistic.

Instead, Parkinson's disease research is increasingly moving toward biological classification.

Future patients may undergo combinations of genetic testing, molecular biomarkers, imaging, and clinical phenotyping to identify the biological mechanisms most relevant to their disease.

Therapies could then be selected according to those biological characteristics rather than clinical diagnosis alone.

This approach resembles precision medicine already used in parts of oncology and some inflammatory diseases.

Importantly, Parkinson's disease has not yet reached that stage.

Whether biologically stratified treatment will produce better outcomes than current approaches remains to be demonstrated.

Combination therapy may also become increasingly important.

If multiple interacting biological pathways contribute simultaneously to disease progression, modifying only one pathway may be insufficient.

Future treatment may therefore require combinations of therapies acting through complementary mechanisms.

Such strategies, however, introduce additional challenges involving safety, tolerability, trial design, drug interactions, and identification of the components responsible for any observed benefit.

These questions remain largely unanswered.

It is easy to interpret unsuccessful trials as scientific failure.

In reality, many have substantially improved the field.

Some have exposed limitations in experimental models and translational assumptions.

They have demonstrated that biological plausibility alone is insufficient.

They have highlighted the importance of target engagement, therapeutic timing, biomarker development, and careful patient selection.

Perhaps most importantly, they have shifted attention away from searching for a single universal mechanism toward understanding the remarkable biological diversity that exists within Parkinson's disease.

Not every negative trial has provided the same level of insight.

Some simply demonstrated that a particular intervention was ineffective.

Others fundamentally changed how researchers design future studies.

Together, however, they have produced a far more sophisticated understanding of the challenges involved in slowing neurodegeneration.

That knowledge is now shaping the next generation of clinical trials.

There is probably no single explanation.

The disease appears biologically heterogeneous.

Different pathological processes may dominate in different individuals.

Important downstream changes may become partially self-sustaining over time.

Therapeutic targets may not always represent the principal drivers of progression.

Some therapies may not adequately engage the relevant molecular species within the appropriate anatomical compartment.

Intervention often begins after substantial biological change has already occurred.

Reliable biomarkers capable of demonstrating disease modification remain under development.

And clinical trials must detect relatively small changes within a disorder that progresses slowly, variably, and across multiple neurological domains.

Each of these challenges may contribute.

Together, they create one of the most difficult problems in modern neurotherapeutics.

At the same time, there are reasons for cautious optimism.

Today's understanding of Parkinson's disease is substantially more sophisticated than it was even a decade ago.

Biomarkers continue to improve.

Biological classification is becoming increasingly feasible.

Clinical trials are becoming more mechanism-based.

Therapeutic strategies are becoming more precise.

None of these advances guarantees that disease modification will succeed.

But they suggest that the field is asking better questions than it did previously.

Perhaps that is the most important lesson.

The future of disease modification may depend less on discovering one extraordinary drug than on understanding the biology of Parkinson's disease with sufficient precision to deliver the right therapy, to the right patient, at the right stage of disease, while measuring the right outcome.

That goal remains challenging.

It is also the direction in which modern Parkinson's disease research is increasingly moving.

—

Think Beyond the Headline.

Despite decades of setbacks, Parkinson's disease research is entering a new era.

Advances in biomarkers, precision medicine, genetics, digital technologies, and earlier intervention are reshaping how researchers think about disease modification.

In the next issue of The Clinical Logic, we'll explore what the next decade may hold—and whether the future lies not in one breakthrough therapy, but in smarter biology, better patient selection, and more precise clinical trials.